Background: End-stage renal disease (ESRD) patients have poor health-related quality of life (HRQOL) comparing to general population and comparable HRQOL to patients with other major chronic diseases. Poor HRQOL is associated with shorter survival. There is a limited threshold to which dialysis dose and parameters management can improve HRQOL in ESRD patients. Numerous studies have sought to find interventions to improve HRQOL. This article is to review the symptoms associated with poor HRQOL and how frequent the quality of life (QOL) should be evaluated to improve the outcome. Summary: It is required by the Center for Medicare and Medicaid Services to evaluate HRQOL of dialysis patients annually. KDIGO recommends the symptoms to be assessed regularly and the treatment is redirected toward a patient-centered care model. Studies have shown that measuring patient-reported outcomes frequently, from 4 times a day to every 3-6 months, without intervention did not improve the HRQOL significantly. Appropriate intervention of the symptoms may improve the quality of life (QOL). Studies in oncology have also showed a similar result. The commonly used tools to evaluate the HRQOL in dialysis patients take up to 30 min for completion. Therefore, frequent assessment of all the symptoms can provide more burden than benefit to the patients. In addition to the annual HRQOL measurements, more frequent evaluation of targeted symptoms can be helpful. For appropriate intervention of the symptoms, effective communication between providers, as well as a multidisciplinary approach, is essential to improve HRQOL and outcomes in dialysis patients. Key Messages: Measurement of patient-reported outcomes may provide an opportunity to improve outcomes in ESRD. The frequent measurement of symptoms and QOL may be burdensome. Consider targeted measurement of symptoms to complement HRQOL measurement. Improved communication and the use of a multidisciplinary team provide mechanisms to improve HRQOL in ESRD.

Keywords:
End-stage renal disease, Quality of life, Frequency of assessment
1.
Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK: Health-related quality of life as a predictor of mortality and hospitalization: the dialysis outcomes and practice patterns study (DOPPS). Kidney Int 2003;64:339-349.
2.
Mittal SK, Ahern L, Flaster E, Maesaka JK, Fishbane S: Self-assessed physical and mental function of haemodialysis patients. Nephrol Dial Transplant 2001;16:1387-1394.
3.
Gabbay E, Meyer KB, Griffith JL, Richardson MM, Miskulin DC: Temporal trends in health-related quality of life among hemodialysis patients in the United States. Clin J Am Soc Nephrol 2010;5:261-267.
4.
Nissenson AR: Improving outcomes for ESRD patients: shifting the quality paradigm. Clin J Am Soc Nephrol 2014;9:430-434.
5.
Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB; HEMO Study Group: Effects of hemodialysis dose and membrane flux on health-related quality of life in the hemo study. Kidney Int 2004;66:355-366.
6.
Weisbord SD, Mor MK, Green JA, Sevick MA, Shields AM, Zhao X, Rollman BL, Palevsky PM, Arnold RM, Fine MJ: Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: a cluster randomized effectiveness trial. Clin J Am Soc Nephrol 2013;8:90-99.
7.
Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, Murtagh FE, Naicker S, Germain MJ, O'Donoghue DJ, Morton RL, Obrador GT: Executive summary of the KDIGO Controversies Conference on supportive care in chronic kidney disease: Developing a roadmap to improving quality care. Kidney Int 2015;88:447-459.
8.
Bakewell AB, Higgins RM, Edmunds ME: Quality of life in peritoneal dialysis patients: decline over time and association with clinical outcomes. Kidney Int 2002;61:239-248.
9.
Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT: Quality of life over time in dialysis: the Netherlands cooperative study on the adequacy of dialysis. NECOSAD Study Group. Kidney Int 1999;56:720-728.
10.
Roumelioti ME, Argyropoulos C, Buysse DJ, Nayar H, Weisbord SD, Unruh ML: Sleep quality, mood, alertness and their variability in CKD and ESRD. Nephron Clin Pract 2010;114:c277-c287.
11.
Abdel-Kader K, Jhamb M, Mandich LA, Yabes J, Keene RM, Beach S, Buysse DJ, Unruh ML: Ecological momentary assessment of fatigue, sleepiness, and exhaustion in ESKD. BMC Nephrol 2014;15:29.
12.
Velikova G, Keding A, Harley C, Cocks K, Booth L, Smith AB, Wright P, Selby PJ, Brown JM: Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer 2010;46:2381-2388.
13.
Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ: Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 2004;22:714-724.
14.
Mills ME, Murray LJ, Johnston BT, Cardwell C, Donnelly M: Does a patient-held quality-of-life diary benefit patients with inoperable lung cancer? J Clin Oncol 2009;27:70-77.
15.
Rosenbloom SK, Victorson DE, Hahn EA, Peterman AH, Cella D: Assessment is not enough: a randomized controlled trial of the effects of HRQL assessment on quality of life and satisfaction in oncology clinical practice. Psychooncology 2007;16:1069-1079.
16.
Weisbord SD, Fried LF, Arnold RM, Fine MJ, Levenson DJ, Peterson RA, Switzer GE: Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 2005;16:2487-2494.
17.
Pisoni RL, Wikström B, Elder SJ, Akizawa T, Asano Y, Keen ML, Saran R, Mendelssohn DC, Young EW, Port FK: Pruritus in haemodialysis patients: international results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant 2006;21:3495-3505.
18.
Mathur VS, Lindberg J, Germain M, Block G, Tumlin J, Smith M, Grewal M, McGuire D; ITCH National Registry Investigators: A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1410-1419.
19.
Belayev LY, Mor MK, Sevick MA, Shields AM, Rollman BL, Palevsky PM, Arnold RM, Fine MJ, Weisbord SD: Longitudinal associations of depressive symptoms and pain with quality of life in patients receiving chronic hemodialysis. Hemodial Int 2015;19:216-224.
20.
Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, Piera L, Held P, Gillespie B, Port FK; Dialysis Outcomes and Practice Patterns Study (DOPPS): Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002;62:199-207.
21.
Weisbord SD, Mor MK, Sevick MA, Shields AM, Rollman BL, Palevsky PM, Arnold RM, Green JA, Fine MJ: Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clin J Am Soc Nephrol 2014;9:1594-1602.
22.
Kang EW, Pike F, Ramer S, Abdel-Kader K, Myaskovsky L, Dew MA, Unruh M: The association of mental health over time with cardiac outcomes in HEMO study patients. Clin J Am Soc Nephrol 2012;7:957-964.
23.
Unruh ML, Buysse DJ, Dew MA, Evans IV, Wu AW, Fink NE, Powe NR, Meyer KB: Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol 2006;1:802-810.
24.
Cohen SD, Patel SS, Khetpal P, Peterson RA, Kimmel PL: Pain, sleep disturbance, and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol 2007;2:919-925.
25.
Jhamb M, Liang K, Yabes J, Steel JL, Dew MA, Shah N, Unruh M: Prevalence and correlates of fatigue in chronic kidney disease and end-stage renal disease: are sleep disorders a key to understanding fatigue? Am J Nephrol 2013;38:489-495.
26.
Abdel-Kader K, Myaskovsky L, Karpov I, Shah J, Hess R, Dew MA, Unruh M: Individual quality of life in chronic kidney disease: influence of age and dialysis modality. Clin J Am Soc Nephrol 2009;4:711-718.
27.
Weisbord SD, Fried LF, Mor MK, Resnick AL, Unruh ML, Palevsky PM, Levenson DJ, Cooksey SH, Fine MJ, Kimmel PL, Arnold RM: Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2007;2:960-967.
28.
Gilbert A, Sebag-Montefiore D, Davidson S, Velikova G: Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol 2015;136:429-439.
29.
Atalay H, Solak Y, Biyik M, Biyik Z, Yeksan M, Uguz F, Guney I, Tonbul HZ, Turk S: Sertraline treatment is associated with an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. Int Urol Nephrol 2010;42:527-536.
30.
Barakzoy AS, Moss AH: Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol 2006;17:3198-3203.
31.
Jaar BG, Chang A, Plantinga L: Can we improve quality of life of patients on dialysis? Clin J Am Soc Nephrol 2013;8:1-4.
32.
Green JA, Mor MK, Shields AM, Sevik MA, Palevsky PM, Fine MJ, Arnold RM, Weisbord SD: Renal provider perceptions and practice patterns regarding the management of pain, sexual dysfunction, and depression in hemodialysis patients. J Palliat Med 2012;15:163-167.
33.
Claxton RN, Blackhall L, Weisbord SD, Holley JL: Undertreatment of symptoms in patients on maintenance hemodialysis. J Pain Symptom Manage 2010;39:211-218.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.